FAQs

What is EU-OPENSCREEN?

EU-OPENSCREEN is a not-for-profit European Research Infrastructure Consortium (ERIC) that supports chemical biology and early drug discovery. It provides researchers with access to advanced technologies, expertise, and compound collections through a distributed network of partner institutions across Europe.

What does EU-OPENSCREEN do?

EU-OPENSCREEN helps scientists identify and develop biologically active small molecules by offering services such as compound screening, medicinal chemistry, and access to high-quality bioactivity data

What services does EU-OPENSCREEN offer?

EU-OPENSCREEN provides a comprehensive portfolio of services, including:

High-throughput compound screening
Medicinal chemistry and hit-to-lead optimisation
Bioactivity data access via an open database
Compound collection and sharing
AI/ML assisted drug discovery
Training and scientific support

What is the EU-OPENSCREEN database?

The European Chemical Biology Database (ECBD) is an open-access database containing millions of bioactivity data points, enabling researchers to explore targets, pathways, and compound effects. For more information visit the ECBD website: https://ecbd.eu/

What kind of compounds are available?

EU-OPENSCREEN offers access to large, curated compound libraries (including over 100,000 molecules) used to identify biologically active compounds and support research projects. More information on our compound libraries can be found here: https://www.eu-openscreen.eu/services/compound-collection.html

What happens to my intellectual property?

The default situation leads to the publication of results in the open access ECBD eventually. The user has the option to request an ‘embargo’ period of up to 36 months to delay the publication of his/her data to allow: In-depth characterization of hits for publication in a scientific peer-reviewed journal and preparing/filing of patents.
All foreground and background IPR stays with those who have contributed to the invention.

Which costs are involved?

If you would like to screen our European Chemical Biology Library (ECBL) with a total of 100.000 compounds, a compound replenishment fee applies:

15.000€ for users from EU-OPENSCREEN member countries (see member countries here)
40.000€ for users from other countries
42.000€ for industry users

Does EU-OPENSCREEN provide funding?

EU-OPENSCREEN does not directly fund research projects, but it supports users in developing grant proposals, building collaborations, and accessing funding opportunities.

How can I access EU-OPENSCREEN services?

Researchers can contact the EU-OPENSCREEN Help Desk for guidance on accessing services, planning projects, and exploring collaboration opportunities.

Can industry partners collaborate with EU-OPENSCREEN?

Yes, innovation is the central goal of EU-OPENSCREEN. We welcome collaborations with the pharmaceutical and biotech sector, specifically in drug discovery, using a pre-competitive model based on open innovation. E-Mail us at: industry@eu-openscreen.eu

Does EU-OPENSCREEN offer training opportunities?

Yes, training is a core activity. EU-OPENSCREEN provides workshops, courses, and knowledge exchange opportunities to support researchers at all career stages. In Autumn every year the Autumn Online Training School takes place over more than three days PhD students, postdoctoral researchers, early-career scientists, and professionals from academia and industry can follow expert-led lectures exploring the latest developments in chemical biology, screening technologies, artificial intelligence, and early drug discovery. For more information on our training see here: https://www.eu-openscreen.eu/services/training.html